Innovent Biologics

07/09/2026

Quality is at the core of everything we do. Innovent Biologics' Suzhou manufacturing base has successfully passed an on-site GMP inspection by the European Medicines Agency, receiving its EU GMP certificate with zero critical findings. The inspection covered the full scope of quality operations, from cell banking and drug substance/product manufacturing to QC labs, data integrity, and supply chain controls, and inspectors specifically noted the strength and maturity of Innovent's quality management system.

With this milestone, Innovent's manufacturing network now meets NMPA, FDA, and EMA standards simultaneously, supporting over 140,000 liters of active production capacity, roughly 20% of China's total biologics capacity.

This certification strengthens the regulatory foundation for Innovent's innovative biologics to enter the EU and other overseas markets, reflecting our continued commitment to bringing high-quality, affordable biologics to patients worldwide.

04/09/2026

We’re proud and grateful to see Innovent Biologics recognized as a 2026 China Outstanding Employer by the China Top Employers Institute, marking our first recognition from the Institute.

This recognition reflects our continued commitment to investing in our people, fostering an open and inclusive workplace, and creating opportunities for employees to learn, grow, and thrive.

Thank you to everyone who contributes to making Innovent a great place to work and grow. We look forward to continuing this journey together and building a stronger future for our people and the biopharmaceutical industry.

26/08/2026

We are pleased to share Innovent's 2026 interim results. More than 3,000 patients are gaining access to Innovent therapies every day, bringing our medicines to more than 10 million patients to date across oncology and general medicine.

We are also expanding our global reach through new collaborations with Takeda, Eli Lilly, and Pfizer, extending the impact of Innovent’s science and medicines to more patients around the world.

Thank you to everyone who has helped make this achievement possible. Fifteen years into the journey, there is much to be proud of, from the reach we have built to the patients we are now able to serve. With even greater opportunity ahead, Innovent remains focused on bringing innovative medicines to more patients around the world.

Read more about our results and dive into the pipeline below. https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html

25/08/2026

Today marks 15 years since Innovent was founded in a small office in Suzhou, at a time when patients across China had very few innovative cancer therapies to turn to.
This film traces that journey, from Tyvyt®’s approval in 2018 and the negotiations that brought its price down by more than 64% to enable its inclusion in China’s National Reimbursement Drug List, to the Patient Assistance Program that has since brought hope to hundreds of thousands of families.
The mission that brought us here has remained the same, but its reach has continued to expand, from fighting cancer to addressing a broader range of chronic diseases and helping people live healthier for longer, including through the approval of the world’s first GCG/GLP-1 dual-target therapy for weight management and glycemic control in people living with obesity and type 2 diabetes.
Through it all, one thing has connected every patient with every person behind the medicine: the belief that someone, somewhere, is working to help them live and live better. Drug makers and patients walk different paths, but they meet at the same crossing, and that meeting point is what has carried us for fifteen years. To everyone who has placed their trust in us: thank you for making that belief real.

Today marks 15 years since Innovent was founded in a small office in Suzhou, at a time when patients across China had very few innovative cancer therapies to turn to. This film traces that journey, from Tyvyt®'s approval in 2018 and the negotiations that brought its price down by more than 64% to e...

25/08/2026

This past weekend, Innovent employees and their families came together to celebrate Family Day, marking 15 years since our founding. Behind every milestone in our mission to empower patients worldwide with affordable, high-quality biopharmaceuticals are families who support long hours and unwavering dedication at home.
In this video, some of our employees' family members share what it means to be part of the Innovent journey, from pride in the work being done to gratitude for the growth it has brought. Their words are a reminder that our progress is never ours alone; it belongs just as much to the people who stand behind us. To every family who shares in this mission with us, thank you for your patience, your encouragement, and your strength.


linkedin:

This past weekend, Innovent employees and their families came together to celebrate Family Day, marking 15 years since our founding. Behind every milestone in our mission to empower patients worldwide with affordable, high-quality biopharmaceuticals are families who support long hours and unwavering...

25/08/2026

Innovent Biologics was founded in 2011 with one goal: to empower patients with affordable, high-quality biopharmaceuticals.
Those early years were about setting the foundations, building the team and the science that everything after would rest on. Between 2016 and 2020, we grew from an R&D-driven biotech into a full biopharmaceutical company, spanning research, manufacturing, and commercialization. And between 2021 and 2025, that groundwork began reaching patients at scale, as new medicines and global partnerships extended our science to more people than ever before.
Now, in 2026, as we mark 15 years, we look back with gratitude for everyone who has been part of this journey, from our people and partners to patients, families, and healthcare providers, and forward to what comes next and the difference we can make together for the patients of tomorrow.

10/08/2026

We are pleased to announce our collaboration with Daiichi Sankyo for the commercialization of VANFLYTA® (quizartinib) in China for eligible patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML).

Approved in China in June 2026 based on results from the Phase 3 QuANTUM-First trial, VANFLYTA® represents an important addition to the treatment landscape for eligible patients with FLT3-ITD-positive AML.

This milestone brings together complementary capabilities with a shared commitment to advancing innovative oncology treatments and addressing the needs of people living with AML. https://www.prnewswire.com/news-releases/innovent-biologics-and-daiichi-sankyo-enter-exclusive-agreement-for-vanflyta-commercialization-in-china-302846648.html

06/08/2026

The first patient has been dosed in a pivotal Phase 3 study evaluating IBI363 (TAK-928) in combination with bevacizumab for advanced colorectal cancer, one of the most challenging cancers to treat with immunotherapy.

Colorectal cancer remains one of the leading causes of cancer death worldwide. Nearly 95% of advanced cases are considered "cold" tumors that respond poorly to current immune checkpoint inhibitors, leaving patients with limited treatment options and an urgent need for new approaches.

IBI363 is a first-in-class PD-1/IL-2α-biased bispecific fusion protein designed to block the PD-1 pathway while selectively activating tumor-specific T cells, with the goal of converting "cold" tumors into ones that can respond to immunotherapy. Encouraging early clinical data presented at ASCO and a Breakthrough Therapy Designation from China's NMPA have supported its continued development.

Now advancing in its third pivotal registrational study through our collaboration with Takeda, IBI363 reflects the potential of next-generation immunotherapies to expand the benefits of immunotherapy to more patients. Every milestone like this brings us one step closer to delivering new treatment options for people facing some of the greatest unmet needs in cancer care.
https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-pivotal-registrational-study-of-ibi363tak-928-pd-1il-2-biased-bispecific-fusion-protein-in-combination-with-bevacizumab-in-late-line-advanced-colorectal-cancer-in-china-302843683.html

15/07/2026

Millions of people living with IgG4-related disease and Sjögren's disease face chronic, relapsing conditions with limited treatment options. For Sjögren's disease, there is still no approved therapy that addresses its underlying systemic nature.

We're excited to announce a new collaboration with Spero Therapeutics on IBI355, a third-generation, Fc-silent anti-CD40L antibody designed to interrupt immune activation without depleting B cells.

Under the agreement, Spero will advance IBI355 into a Phase 2 study for IgG4-related disease in 2027, while Innovent will lead a parallel Phase 2 trial in China for Sjögren's disease. Together, we're advancing the science by leveraging each organization's expertise and strengths.

This collaboration reflects a shared commitment to advancing immunology and developing meaningful new treatment options for patients living with these complex autoimmune diseases around the world.

https://www.prnewswire.com/news-releases/innovent-biologics-and-spero-therapeutics-announce-exclusive-license-for-ibi355-sp001-a-phase-2-ready-third-generation-anti-cd40l-antibody-302824889.html

01/07/2026

Innovent and Eli Lilly and Company have entered into a distribution and promotion agreement for Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China. Building on the complementary strengths of both companies, the collaboration combines Lilly's leadership in innovative medicine with Innovent's established oncology commercialization capabilities to help expand patient access to an important breast cancer therapy. Read more about the agreement in the link below.

Approved in China across multiple HR-positive, HER2-negative breast cancer indications, Verzenios® was the first CDK4 & 6 inhibitor included in China's National Reimbursement Drug List and remains broadly reimbursed for both early and advanced disease.

This marks the eighth collaboration between Innovent and Lilly and adds the 19th product to Innovent's portfolio. We are pleased to build on our longstanding partnership with Lilly and look forward to bringing this proven treatment to more breast cancer patients across China, advancing our shared commitment to improving patient outcomes.

https://www.prnewswire.com/news-releases/innovent-biologics-and-lilly-enter-into-commercialization-agreement-for-verzenios-abemaciclib-in-mainland-china-302814010.html